Mikko Lehtovirta<p>From our team: Polygenic scores (PGSs) hold promise for tailoring type 2 diabetes risk prediction and treatment, especially in younger and lean individuals—but clinical use is still limited by ancestry bias, weak effect sizes, and missing heritability. Source: <a href="http://bit.ly/3FWSp32" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">http://</span><span class="">bit.ly/3FWSp32</span><span class="invisible"></span></a> <a href="https://mastodontti.fi/tags/diabetes" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>diabetes</span></a> <a href="https://mastodontti.fi/tags/diabetologia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>diabetologia</span></a></p>